EU Clears Oral Wegovy Pill as GLP-1 Drugs Show 50% Lower Lung Cancer Spread
Over 10,000 early-stage cancer patients on GLP-1 therapies saw lung cancer progression cut by roughly 50%, while a 137,000-patient breast cancer study reported 95% five-year survival versus 89.5% in nonusers. European regulators recommended Novo Nordisk’s Wegovy pill, positioning it as the EU’s first oral anti-obesity treatment and expanding market reach.
1. Cancer Research Findings
A Cleveland Clinic Cancer Institute study of over 10,000 early-stage cancer patients found those on GLP-1 therapies experienced roughly 50% lower lung cancer progression compared with patients on other diabetes drugs. In a separate analysis of 137,000 breast cancer patients, 95% of GLP-1 users were alive at five years versus 89.5% of nonusers.
2. EU Approval of Wegovy Pill
The European Medicines Agency recommended approval of Novo Nordisk’s Wegovy oral pill, making it the first tablet formulation approved for obesity treatment in the European Union. This approval paves the way for launch ahead of competing injectable therapies and addresses patient demand for non-invasive weight-loss options.
3. Market Implications
If cancer-related benefits are confirmed in future trials, GLP-1 therapies could tap into oncology markets currently valued in the tens of billions, adding to the obesity and diabetes franchises. The EU approval of an oral formulation further broadens commercial reach and could accelerate revenue growth in key regions.
4. Future Outlook
Novo Nordisk plans to initiate randomized trials to establish causal links between GLP-1 use and improved cancer outcomes, with initial results expected within 12–18 months. The company will also prepare manufacturing and supply chains to support anticipated demand for Wegovy in Europe and potential label expansions.